Protect Yourself While There’s Still Time …

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

Daniel Janney Biography and Net Worth

Director of Krystal Biotech

Dan Janney is the Managing Partner of Alta Partners. Dan Janney joined Alta Partners at its founding in 1996. He has nearly 25 years of successful early-stage investing experience in life sciences. Dan’s focus on working with talented entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery has led to the funding and development of 35 companies. Prior to Alta, Dan was a senior investment banker at Montgomery Securities. Dan is currently on the board of directors of several public and private companies, including Allakos (NASDAQ: ALLK), Be Biopharma, Curasen Therapeutics, ImmuneID, Krystal Biotech (NASDAQ: KYRS), Lassen Therapeutics, Novome Biotechnologies, and Prolacta Bioscience. In addition, he led Alta’s investments in Astex Pharmaceuticals (acquired by Supergen), Cellective (acquired by Medimmune), ChemGenex (ASX: CXS acquired by Cephalon), CoTherix (NASDAQ: CTRX acquired by Actellion), Definity Health (acquired by United Health), Dynavax (NASDAQ: DVAX), Endonetics (acquired by Medtronic), Esperion Therapeutics (NASDAQ: ESPR), Ilex Oncology (NASDAQ: ILXO acquired by Millennium Pharmaceuticals), InterMune (NASDAQ: ITMN acquired by Roche), LJL Biosystems (NASDAQ: LJLB acquired by Molecular Devices), Mako Surgical (NASDAQ: MAKO acquired by Stryker) and Triangle Pharmaceuticals (NASDAQ: VIRS acquired by Gilead). Dan is a member of The President’s Council of the J. David Gladstone Institutes and the chair of the Board of Directors of the California Academy of Sciences. He also serves on the Board of Regents of Georgetown University. He holds a B.A. from Georgetown University and a Master of Business Administration from the Anderson School at the University of California, Los Angeles.

What is Daniel Janney's net worth?: The estimated net worth of Daniel Janney is at least $19.81 million as of June 8th, 2023. Mr. Janney owns 126,297 shares of Krystal Biotech stock worth more than $19,813,473 as of April 27th. This net worth approximation does not reflect any other investments that Mr. Janney may own. Learn More about Daniel Janney's net worth.
How do I contact Daniel Janney?: The corporate mailing address for Mr. Janney and other Krystal Biotech executives is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. Krystal Biotech can also be reached via phone at (412) 586-5830 and via email at [email protected]. Learn More on Daniel Janney's contact information.
Has Daniel Janney been buying or selling shares of Krystal Biotech?: Daniel Janney has not been actively trading shares of Krystal Biotech within the last three months. Most recently, Daniel Janney sold 31,065 shares of the business's stock in a transaction on Thursday, June 8th. The shares were sold at an average price of $128.11, for a transaction totalling $3,979,737.15. Following the completion of the sale, the director now directly owns 126,297 shares of the company's stock, valued at $16,179,908.67. Learn More on Daniel Janney's trading history.
Who are Krystal Biotech's active insiders?: Krystal Biotech's insider roster includes Daniel Janney (Director), Krish Krishnan (CEO), Suma Krishnan (COO), Kathryn Romano (CAO), and Dino Rossi (Director). Learn More on Krystal Biotech's active insiders.
Are insiders buying or selling shares of Krystal Biotech?: In the last year, insiders at the sold shares 13 times. They sold a total of 279,680 shares worth more than $32,580,188.72. The most recent insider tranaction occured on March, 11th when insider Suma Krishnan sold 25,000 shares worth more than $4,274,000.00. Insiders at Krystal Biotech own 14.1% of the company. Learn More about insider trades at Krystal Biotech.
Information on this page was last updated on 3/11/2024.

Daniel Janney Insider Trading History at Krystal Biotech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/8/2023	Sell	31,065	$128.11	$3,979,737.15	126,297
5/19/2023	Sell	50,000	$95.02	$4,751,000.00	157,362
5/9/2023	Sell	17,100	$90.74	$1,551,654.00	207,362
4/19/2023	Sell	7,900	$90.32	$713,528.00	224,462
8/30/2019	Sell	88,684	$46.46	$4,120,258.64	35,131
9/22/2017	Buy	200,000	$10.00	$2,000,000.00

Daniel Janney Buying and Selling Activity at Krystal Biotech

Krystal Biotech Company Overview

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Today's Range

Now: $156.88

$153.79

$158.93

50 Day Range

MA: $164.33

$108.01

$180.42

2 Week Range

Now: $156.88

$82.09

$189.97

Volume

165,898 shs

Average Volume

363,777 shs

Market Capitalization

$4.47 billion

P/E Ratio

1,961.25

Dividend Yield

N/A

Beta

0.85